Studies performed involving the administration of humanized monoclonal antibodies against IL-5, namely reslizumab and mepolizumab, found that there was significant reduction in the size of nasal polyps as well as peripheral blood eosinophil level [70,71], which reduced the necessity for revision surgeries [72]. This evidence concerns the gene IL5 and nasal cavity polyp.